Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ENDRA Life Sciences (NDRA) Accumulated Expenses (2016 - 2025)

ENDRA Life Sciences has reported Accumulated Expenses over the past 6 years, most recently at $101459.0 for Q4 2021.

  • Quarterly Accumulated Expenses rose 110.23% to $101459.0 in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $101459.0 through Dec 2021, up 110.23% year-over-year, with the annual reading at $101459.0 for FY2021, 110.23% up from the prior year.
  • Accumulated Expenses was $101459.0 for Q4 2021 at ENDRA Life Sciences, down from $196079.0 in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $211702.0 in Q1 2021 and troughed at $29302.0 in Q4 2018.
  • The 5-year median for Accumulated Expenses is $81157.0 (2017), against an average of $100710.8.
  • Year-over-year, Accumulated Expenses surged 223.74% in 2019 and then crashed 49.13% in 2020.
  • A 5-year view of Accumulated Expenses shows it stood at $40578.0 in 2017, then dropped by 27.79% to $29302.0 in 2018, then surged by 223.74% to $94862.0 in 2019, then plummeted by 49.13% to $48260.0 in 2020, then skyrocketed by 110.23% to $101459.0 in 2021.
  • Per Business Quant, the three most recent readings for NDRA's Accumulated Expenses are $101459.0 (Q4 2021), $196079.0 (Q3 2021), and $211702.0 (Q1 2021).